- The distribution agreement was signed at the CPHI fair in Frankfurt on Oct. 28.
- The agreement covers SAN HQ, SAN-HQ GMP, M-SAN HQ, and M-SAN HQ GMP nucleases.
- These nucleases are used for nucleic acid removal in gene therapy and vaccine production.
- M-SAN HQ is optimized for 125–200 mM NaCl, while SAN HQ is active above 300 mM NaCl.
Agreement Details
The distribution agreement between Brenntag and ArcticZymes was signed at the CPHI fair in Frankfurt on October 28. It covers the exclusive distribution of salt-active nucleases: SAN HQ, SAN-HQ GMP, M-SAN HQ, and M-SAN HQ GMP.
Applications in Bioprocessing
These nucleases are designed for efficient removal of nucleic acids in gene therapy, vaccine production, and other bioprocessing workflows. The biopharmaceutical industry is rapidly expanding, driven by advancements in gene and cell therapies and biopharmaceutical vaccines.
Product Specifications
M-SAN HQ is optimized for use in 125–200 mM NaCl, making it ideal for direct use in cell media and as a replacement for traditional nucleases. SAN HQ remains active even above 300 mM NaCl, suitable for de-aggregation and high-yield purification workflows. Both enzymes are available in GMP grade, facilitating the transition from pilot scale to manufacturing.
Strategic Benefits
The partnership leverages Brenntag's distribution channels to broaden access to ArcticZymes' pioneering endonucleases, addressing the dynamic expansion of the biopharma market. Brenntag gains access to crucial nuclease products and ArcticZymes' expertise, enhancing downstream bioprocessing capabilities.
